<DOC>
	<DOCNO>NCT02064582</DOCNO>
	<brief_summary>The study do find whether combine two FDA approve drug along radiation therapy treatment high risk localize prostate cancer safe well tolerate .</brief_summary>
	<brief_title>Enzalutamide Hormone Therapy Before , During , After Radiation High Risk Localized Prostate Cancer</brief_title>
	<detailed_description>- pilot study assess safety tolerability combine enzalutamide gonadotropin-releasing hormone agonist ( GnRH ) external beam radiation - Correlative imaging tissue biopsy analysis perform assess radiographic response enzalutamide plus gonadotropin-releasing hormone agonist ( GnRH ) therapy well intratumoral androgen signal</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>histologically proven adenocarcinoma prostate within 6 month screen Eastern Cooperative Oncology Group ( ECOG ) score 02 adequate organ blood marrow function must candidate longterm androgen deprivation combination external beam radiation treatment high risk prostate cancer patient must permit targeted prostate biopsy time study initiation begin radiation treatment men sexually active female partner childbearing potential mush agree use adequate contraception prior treatment agent know endocrine effect prostate cancer treatment corticosteroid within 4 week enrollment treatment androgen within 6 month enrollment may receive investigational agent Prostate specific antigen great 160ng/dL history malignancy ( nonmelanoma skin cancer ) within 5 year uncontrolled intercurrent illness cardiovascular event within 6 month enrollment seizure seizure disorder history contraindication MRI pacemaker , clip , etc</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>prostate cancer , enzalutamide , radiation , hormone therapy</keyword>
</DOC>